zeus retweeted
Shuts down Ebola research - Massive Ebola outbreak
Closes CDC Parasitology division - Huge parasitic diarrhoea outbreak
Defunds screwworm research - screwworm comes back to the US
Bashes vaccines - measles roars back
Ladies and gentlemen I give you Health Secretary RFK Jr
$SGMO owns valuable technologies. Will it survive the current money crunch and realize its potential? It’s has been painful to own the stock.
7
1,456
During a gathering with friends past weekend, one asked the question of what was it like before the Big Bang? I answered him that there was no “before” the Big Bang. Time and space only started with the Big Bang!
106
Efficacy, ease of administration, and once-and-done will make $NTLA products the standards of care for HAE and ATTR. Annual sales will be more $10B by 2034. What should be the current valuation?
1
11
927
$SGMO Early treatment with ST-920 is key to restore kidney function. Patients with mild kidney damage (eGFR>60) show the most improvement. This is further supported by results from female patients. Miracle drug for Fabry patients!
$SGMO Fabry deal will be done within 4 weeks. The upfront money will be less than expected (SGMO demands for 2 years of funding of ~250 to 300M). Now upfront will be ~150M with approval of additional $80M. ~15% royalty.
$INMB Can anyone analyze the psychology for Monday morning? If totally negative, Friday after hours would be perfect. If blown away positive, why wait for 3 days?
1
1
620
$SGMO “Furthermore, a mean annualized eGFR slope of 1.747 mL/min/1.73m2/year (95% CI: -0.106, 3.601) was observed for the 19 patients who have achieved 104-weeks of follow-up”
Patients gained years of kidney function after two years on treatment.
$SGMO As the median age of patients is in their 40s, most of them will gain back about ~5 years of kidney function in terms of eGFR after two years. The general population loses about 6 to 7 points between the age 40 and 50. It’s a miracle drug for Fabry patients.
With mature data, approval is near certainty both in US and EU. $SGMO needs to get an experienced partner. It will reach peak sales of over 1B for over a decade.
$SGMO ZINC FINGER SUPPRESSORS (ZFRs) or ACTIVATORS (ZFAs) have advantages. Tough investing and regulatory environments will bankrupt some of them. A good CEO will be the key. Survivors will be big.
6
621
Wonderful commentary on the media coverage of India-Pakistan conflict: lost truth/facts/integrity, dailymirror.lk/opinion/Indo-…
1
145
In the upcoming deal for ST-920, it is likely to include equity investment due to the current dismal share price of $SGMO. Possible 9.9% equity investment for $120M in addition to up front payment of $100 to 200M.
$SGMO Transformative treatments such as ST-920 and NTLA-2002 will be approved regardless of who’s in charge of the FDA. The only downside for ST-920 seems to be that it can only be used for about half of the patients due to seropositivity for AAV6.
1
15
1,326
$SGMO The new publication on Fidanacogene Elaparvovec (Hem B gene therapy) should dispel any doubts on the duration of AAV based treatment. There’s a minimal decline for 6 years. nejm.org/doi/full/10.1056/NE…
1
16
918




